Skip to main content

Adequan i.m. Single Dose

This treatment applies to the following species:
Company: American Regent

polysulfated glycosaminoglycan

Solution 500 mg/5 mL

For Intramuscular Use In Horses

Adequan i.m. Single Dose Caution

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description

Each 5 milliliters of Adequan® i.m. contains 500 mg of Polysulfated Glycosaminoglycan (PSGAG) and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. Sodium Chloride may be added to adjust tonicity.

Pharmacology

Polysulfated Glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components. PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration in traumatized equine carpal and hock joints.

Adequan i.m. Single Dose Indications

Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

Dosage and Administration

The recommended dose of Adequan® i.m. in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan® i.m. with other drugs or solvents.

Contraindications

There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.

Warnings

Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children.

Precautions

The safe use of Adequan® i.m. in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.

ANIMAL SAFETY: Toxicity studies were conducted in horses. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal had any clinical or laboratory evidence of toxicity.

STORAGE CONDITIONS: Store at 20°-25°C (68°-77°F); (See USP Controlled Room Temperature). Discard unused portion.

Dispose of spent needles in accordance with all federal, state and local environmental laws.

How Supplied

Adequan® i.m. solution, 500 mg/5 mL (100 mg/mL) in a 5 mL single dose glass vial.

NDC 10797-995-70 5 mL

5 mL Single Dose Vials

Packaged 7 vials per box

AMERICAN REGENT, INC., ANIMAL HEALTH, Shirley, NY 11967

(1-888-354-4857)

Approved by FDA under NADA # 140-901

Made in U.S.A.

IN99501

Rev. 9/2021

MG #44455

CPN: 1039002.9

AMERICAN REGENT, INC.
Animal Health Division

625 BROADHOLLOW ROAD, 4TH FLOOR, MELVILLE, NY, 11747
Telephone:   631-924-4000
Order Desk:   800-458-0163
Technical Service:   631-924-4000
Fax:   631-205-2013
Website:   www.aranimalhealth.com
    www.adequan.com
    www.betavetequine.com
THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.

Animalytix

Copyright © 2024 Animalytix LLC. Updated: 2024-02-27